Key facts
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Qiarui Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Qiarui Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qiarui Biology
Manufacturer of blood purification consumables and targeted adsorption therapy devices intended for hospitals, nephrology and rheumatology departments, and blood purification centers. The company is engaged in the R&D and production of PEDAC-based plasma-directed enrichment and adsorption systems, including targeted adsorption perfusion devices, thereby enabling clients to rapidly and safely reduce pathological blood components.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- charitybiotech.cn/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Qiarui Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qiarui Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qiarui Biology in its N-PORT filings yet. We sweep new filings monthly.